Jade Biosciences, Inc. 8-K

What Happened Jade Biosciences, Inc. filed an 8-K on April 22, 2026, reporting that its Board appointed Andrew King, BVMS, Ph.D., as President, Research & Development, effective April 18, 2026. Dr. King was previously the company’s Chief Scientific Officer and Head of Research & Development.

Key Details

• Appointment effective date: April 18, 2026.
• Filing date: Form 8-K filed April 22, 2026 (Item 5.02: departure/election of officers/directors).
• Dr. King’s prior role: Chief Scientific Officer and Head of Research & Development.
• Compensation: No changes were made to Dr. King’s compensation in connection with the appointment.

Why It Matters This is an internal promotion that keeps R&D leadership continuity—important for a biotech where research progress and pipeline management are central to value. Because compensation was unchanged, there is no immediate impact on corporate expenses disclosed in the filing. Investors tracking management stability, governance, or the company’s research strategy should note the leadership update reported under Item 5.02 of the 8-K.